采纳股份(301122) - 2025 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2025 was ¥72,709,290.01, a decrease of 34.28% compared to ¥110,633,038.63 in the same period last year[5] - Net profit attributable to shareholders was ¥7,680,170.44, down 69.34% from ¥25,045,442.29 year-on-year[5] - The net profit after deducting non-recurring gains and losses was ¥3,751,442.88, reflecting a decline of 78.81% compared to ¥17,703,983.31 in the previous year[5] - Basic and diluted earnings per share were both ¥0.06, a decrease of 70.00% from ¥0.20 in the same period last year[5] - Operating profit for the current period was ¥8,771,668.48, down 70.4% from ¥29,566,811.75 in the previous period[26] - Net profit for the current period was ¥7,263,799.94, a decline of 70.0% compared to ¥25,045,442.29 in the previous period[26] - Total comprehensive income attributable to the parent company was 7,676,341.95, compared to 25,045,442.29 in the previous period[27] Cash Flow and Assets - The net cash flow from operating activities decreased by 40.24%, amounting to ¥24,974,256.66, down from ¥41,790,114.16 in the previous year[11] - The company's cash and cash equivalents decreased to ¥323,052,115.34 from ¥331,714,012.93, a reduction of 2.0%[21] - Total current assets decreased to ¥1,025,083,767.94 from ¥1,134,334,117.19, a decline of 9.6%[21] - Total non-current assets increased to ¥944,403,424.89 from ¥846,590,930.24, an increase of 11.5%[22] - Total liabilities decreased to ¥147,823,364.57 from ¥166,483,138.90, a reduction of 11.1%[23] - Total equity increased to ¥1,821,663,828.26 from ¥1,814,441,908.53, an increase of 0.1%[23] - Cash inflow from investment activities totaled 608,289,255.61, compared to 317,427,371.11 in the previous period, indicating a significant increase[30] - Cash flow from operating activities decreased by 15% year-over-year[29] - The company’s total cash outflow from operating activities was 83,163,457.06, slightly down from 85,841,219.67 in the previous period[29] Shareholder Information - Total number of common shareholders at the end of the reporting period is 6,731[14] - The largest shareholder, Lu Jun, holds 28.29% of shares, totaling 34,580,000 shares, with 25,935,000 shares pledged[14] - The second-largest shareholder, Lu Weiwei, holds 16.16% of shares, totaling 19,760,000 shares[14] - The top ten shareholders collectively hold significant stakes, with the top three shareholders alone accounting for over 50% of total shares[14] - The company has not disclosed any other significant shareholder relationships or actions that may affect shareholding dynamics[15] - The company is under high executive lock-up restrictions, with all major shareholders' shares subject to lock-up during their tenure[17] Operational Challenges - The company is currently facing an FDA import warning affecting its subsidiary, Jiangsu Caina Medical Technology Co., which may significantly impact future revenue and profits[19] - The company is actively communicating with the FDA to resolve the import warning issue, but the timeline for resolution remains uncertain[19] - The company emphasizes the importance of investor awareness regarding potential risks associated with the FDA warning[19] Other Financial Metrics - Total operating costs decreased to ¥69,274,853.76 from ¥79,627,515.63, reflecting a reduction of 13.0%[25] - Investment income decreased by 59.70% to ¥2,128,789.69, down from ¥5,281,918.63 in the previous year due to reduced interest from redeemed financial products[10] - The company experienced a 97.54% reduction in asset impairment losses, reporting a loss of ¥291,950.27 compared to a loss of ¥11,871,141.16 in the previous year, primarily due to prior year provisions related to FDA issues[10] - The company incurred a foreign currency translation loss of -3,828.49[27]